PIBI BOUDA: Open Payments
NPI 1235836982 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,269 in 64 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $2,885 · 2025 $1,269
Food & beverage: $1,269
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $359 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $213 |
| Janssen Biotech, Inc. | 8 | $157 |
| Lilly USA, LLC | 5 | $115 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $105 |
| Madrigal Pharmaceuticals | 5 | $95 |
| Mirum Pharmaceuticals, Inc. | 1 | $35 |
| GENZYME CORPORATION | 1 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
Products named: RINVOQ, ENTYVIO, SKYRIZI, TREMFYA, OMVOH, XIFAXAN, REZDIFFRA, DUPIXENT.
Industry payments across MO — which companies pay providers there.
